Key result
Presentation in 2015 compared to 2011 was associated with an increase in reperfusion therapy among eligible STEMI patients (59.7% vs 54.0%, p<0.0001), but no significant change in in-hospital death.
Why the study?
Despite improvements in acute cardiovascular care access and capacity, national changes in STEMI characteristics, in-hospital management, and outcomes in China required assessment.
Observational
Yes
Absolute Event Rate: 59.7% vs 54%
p-value: p=<0.0001
Despite an increase in the use of acute reperfusion therapies for eligible STEMI patients in China from 2011 to 2015, in-hospital mortality did not significantly improve, largely driven by increasing prehospital delays.
Increased reperfusion without mortality benefit in STEMI; leaves open whether prehospital delays limit impact and requires prospective study.
OBJECTIVE: Access to acute cardiovascular care has improved and health services capacity has increased over the past decades. We assessed national changes in (1) patient characteristics, (2) in-hospital management and (3) patient outcomes among patients presenting with ST segment elevation myocardial infarction (STEMI) in 2011-2015 in China. METHODS: In a nationally representative sample of hospitals in China, we created two random cohorts of patients in 2011 and 2015 separately. We weighted our findings to estimate nationally representative numbers and assessed changes from 2011 to 2015. Data were abstracted from medical charts centrally using standardised definitions. RESULTS: While the proportion of patients with STEMI among all patients with acute myocardial infarction decreased over time from 82.5% (95% CI 81.7 to 83.3) in 2011 to 68.5% (95% CI 67.7 to 69.3) in 2015 (p<0.0001), the weighted national estimate of patients with STEMI increased from 210 000 to 380 000. The rate of reperfusion eligibility among patients with STEMI decreased from 49.3% (95% CI 48.1 to 50.5) to 42.2% (95% CI 41.1 to 43.4) in 2015 (p<0.0001); ineligibility was principally driven by larger proportions with prehospital delay exceeding 12 hours (67.4%-76.7%, p<0.0001). Among eligible patients, the proportion receiving reperfusion therapies increased from 54% (95% CI 52.3 to 55.7) to 59.7% (95% CI 57.9 to 61.4) (p<0.0001). Crude and risk-adjusted rates of in-hospital death did not differ significantly between 2011 and 2015. CONCLUSIONS: In this most recent nationally representative study of STEMI in China, the use of acute reperfusion increased, but no significant improvement occurred in outcomes. There is a need to continue efforts to prevent cardiovascular diseases, to monitor changes in in-hospital treatments and outcomes, and to reduce prehospital delay.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2021) conducted an observational in ST segment elevation myocardial infarction (STEMI). Presentation in 2015 vs. Presentation in 2011 was evaluated on Proportion receiving reperfusion therapies among eligible patients (p=<0.0001). Presentation in 2015 compared to 2011 was associated with an increase in reperfusion therapy among eligible STEMI patients (59.7% vs 54.0%, p<0.0001), but no significant change in in-hospital death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: